CRMD Quote, Financials, Valuation and Earnings

Protagenic Therapeutics has a net margin of 52.82% compared to Cormedix's net margin of --. Cormedix's return on equity of 23.7% beat Protagenic Therapeutics's return on equity of --.

Cormedix has a consensus price target of $19.00, signalling upside risk potential of 70.71%. On the other hand Protagenic Therapeutics has an analysts' consensus of -- which suggests that it could grow by 6392.75%. Given that Protagenic Therapeutics has higher upside potential than Cormedix, analysts believe Protagenic Therapeutics is more attractive than Cormedix.

Cormedix has a beta of 1.581, which suggesting that the stock is 58.146% more volatile than S&P 500. In comparison Protagenic Therapeutics has a beta of 0.354, suggesting its less volatile than the S&P 500 by 64.562%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagenic Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cormedix pays -- of its earnings as a dividend. Protagenic Therapeutics pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $39.1M, which are larger than Protagenic Therapeutics quarterly revenues of --. Cormedix's net income of $20.6M is higher than Protagenic Therapeutics's net income of -$1.4M. Notably, Cormedix's price-to-earnings ratio is 50.59x while Protagenic Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is 8.32x versus 0.13x for Protagenic Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of 52.82% compared to Cormedix's net margin of -108.46%. Cormedix's return on equity of 23.7% beat Ultragenyx Pharmaceutical's return on equity of -205.06%.

Cormedix has a consensus price target of $19.00, signalling upside risk potential of 70.71%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $87.21 which suggests that it could grow by 219.34%. Given that Ultragenyx Pharmaceutical has higher upside potential than Cormedix, analysts believe Ultragenyx Pharmaceutical is more attractive than Cormedix.

Cormedix has a beta of 1.581, which suggesting that the stock is 58.146% more volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.261, suggesting its less volatile than the S&P 500 by 73.884%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cormedix pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $39.1M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $139.3M. Cormedix's net income of $20.6M is higher than Ultragenyx Pharmaceutical's net income of -$151.1M. Notably, Cormedix's price-to-earnings ratio is 50.59x while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is 8.32x versus 4.32x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 52.82% compared to Cormedix's net margin of 26.7%. Cormedix's return on equity of 23.7% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Cormedix has a consensus price target of $19.00, signalling upside risk potential of 70.71%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 32.96%. Given that Cormedix has higher upside potential than Regeneron Pharmaceuticals, analysts believe Cormedix is more attractive than Regeneron Pharmaceuticals.

Cormedix has a beta of 1.581, which suggesting that the stock is 58.146% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.32% to investors and pays a quarterly dividend of $0.88 per share. Cormedix pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $39.1M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Cormedix's net income of $20.6M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Cormedix's price-to-earnings ratio is 50.59x while Regeneron Pharmaceuticals's PE ratio is 13.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is 8.32x versus 4.44x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals has a net margin of 52.82% compared to Cormedix's net margin of 21.46%. Cormedix's return on equity of 23.7% beat Rigel Pharmaceuticals's return on equity of --.

Cormedix has a consensus price target of $19.00, signalling upside risk potential of 70.71%. On the other hand Rigel Pharmaceuticals has an analysts' consensus of $33.74 which suggests that it could grow by 75.01%. Given that Rigel Pharmaceuticals has higher upside potential than Cormedix, analysts believe Rigel Pharmaceuticals is more attractive than Cormedix.

Cormedix has a beta of 1.581, which suggesting that the stock is 58.146% more volatile than S&P 500. In comparison Rigel Pharmaceuticals has a beta of 1.264, suggesting its more volatile than the S&P 500 by 26.398%.

Cormedix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cormedix pays -- of its earnings as a dividend. Rigel Pharmaceuticals pays out -- of its earnings as a dividend.

Cormedix quarterly revenues are $39.1M, which are smaller than Rigel Pharmaceuticals quarterly revenues of $53.3M. Cormedix's net income of $20.6M is higher than Rigel Pharmaceuticals's net income of $11.4M. Notably, Cormedix's price-to-earnings ratio is 50.59x while Rigel Pharmaceuticals's PE ratio is 9.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cormedix is 8.32x versus 1.69x for Rigel Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.